Plasmodium falciparum multidrug resistance 1gene polymorphisms associated with outcomes after antimalarial treatment

Abstract

Article summaryThis study suggests that: 1) patients given AL infected with parasites carrying N86 were statistically more likely to experience a recurrent infection; 2) patients given ASAQ infected with parasites carrying 86Y were statistically more likely to experience a recurrent infection.BackgroundPlasmodium falciparum multidrug resistance transporter 1(Pfmdr1) gene mutations are associated with altered response to artemisinin-based combination therapies (ACTs), particularly those containing the partner drugs lumefantrine and amodiaquine (i.e., artemether-lumefantrine [AL] and artesunate-amodiaquine [ASAQ]). Past studies ofPfmdr1single nucleotide polymorphisms (SNPs) at codons 86, 184, and 1246 have shown different responses to AL and ASAQ.MethodsTo determine whether infection with parasites carrying specificPfmdr1SNPs leads to increased risk of recurrent parasitemia (recrudescent or new infection), data from 4,129 samples from 16 therapeutic efficacy studies from 13 African countries between 2013–2019 were analyzed.ResultsPatients treated with AL and infected with parasites carryingPfmdr1N86 were at greater risk of treatment failure than those whose parasites carried 86Y. After treatment with ASAQ, individuals infected with parasites that carriedPfmdr186Y were more likely to experience a recurrent infection.ConclusionsOur results support prior studies that suggested: 1) patients given AL and infected with parasites carrying N86 were more likely to experience a recurrent infection; 2) patients given ASAQ and infected with parasites carrying 86Y were more likely to experience recurrent infection. These findings suggest that ACT andPfmdr1genotype may influence outcome afterP. falciparuminfection.